Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Adverum Biotechnologies, Inc.: Bylaws amended and restated in their entirety.
- Change
- bylaw amendment
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Adverum Biotechnologies, Inc.: Certificate of incorporation amended and restated in its entirety.
- Change
- charter amendment
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Adverum Biotechnologies, Inc. underwent a change of control involving Eli Lilly and Company for $3.56 per Share in cash plus contingent value rights (closed 2025-12-09).
- Action
- change of control
- Counterparty
- Eli Lilly and Company
- Consideration
- $3.56 per Share in cash plus contingent value rights
- Closing
- 2025-12-09
Exact text from the filing
to purchase all of the issued and outstanding shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Company Common Stock”) in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest (the “Closing Amount”) and less any applicable tax withholding, plus (ii) one non-tradable contingent value right
View on SEC.gov